1 Neurologisk Klinik, Neurocentret, Rigshospitalet, The Capital Region of Denmark
BACKGROUND: A major problem in the treatment of multiple sclerosis (MS) patients with interferon-beta (IFN-β) is the development of neutralising antibodies (NAbs). High levels of NAbs block the induction of IFN-β-inducible markers, including Myxovirus Resistance Protein A (encoded by the MX1 gene), resulting in a loss of bioactivity and therapeutic benefit. OBJECTIVE: The primary objective of this study is to investigate the in vivo biological response to interferon-alpha (IFN-α) in MS patients, who have developed neutralising antibodies (NAbs) against IFN-β. DESIGN/METHODS: The study was an open-label phase II study in 10 patients with relapsing-remitting MS with persisting NAbs against IFN-β and absent in vivo mRNA MxA response. We used in vivo induction of MX1 mRNA and other IFN-inducible genes as measure of the biological response. The primary endpoint was the in vivo mRNA MX1 response after an injection of IFN-α compared with the response after an injection of IFN-β. RESULTS: In all 10 patients we found high MX1 expression after injection of IFN-α 6 MIU, indicating a preserved in vivo response to IFN-α. We measured the gene expression index of immune system genes in blood cells from the 10 NAb-positive patients after IFN-α treatment and 10 NAb-negative patients after injection of IFN-β. We found a significantly increased expression of a number of genes, including MX1, IFI27, IL10 and TNFSF10 (encoding TRAIL) in the NAb-positive patients treated with IFN-α. INTERPRETATION: IFN-α could be a therapeutic option in patients, who have lost the biological response to IFN-β because of NAbs against IFN-β. ClinicalTrials gov. Identifier: NCT01171209.
Multiple Sclerosis and Related Disorders, 2013, Vol 2, Issue 2, p. 141-6